TECH BIO-TECHNE Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: TECH

Price (delayed)

$505.26

Market cap

$19.75B

P/E Ratio

139.57

Dividend/share

$1.28

EPS

$3.62

Enterprise value

$19.97B

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's ...

Highlights
The gross profit rose by 31% YoY and by 11% QoQ
The revenue has grown by 26% YoY and by 10% from the previous quarter
BIO-TECHNE's debt has increased by 44% QoQ but it has decreased by 3% YoY
TECH's P/E is 134% above its 5-year quarterly average of 59.6 and 79% above its last 4 quarters average of 78.0
TECH's EPS is down by 40% year-on-year and by 24% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.bio-techne.com/
Peers: TMO BIO BDX DHR

Key stats

What are the main financial stats of TECH
Market
Shares outstanding
39.08M
Market cap
$19.75B
Enterprise value
$19.97B
Valuations
Price to earnings (P/E)
139.57
Price to book (P/B)
12.43
Price to sales (P/S)
21.03
EV/EBIT
122.53
EV/EBITDA
79.64
EV/Sales
21.45
Earnings
Revenue
$931.03M
EBIT
$162.95M
EBITDA
$250.7M
Free cash flow
$307.86M
Per share
EPS
$3.62
Free cash flow per share
$7.95
Book value per share
$40.65
Revenue per share
$24.03
TBVPS
$20.75
Balance sheet
Total assets
$2.26B
Total liabilities
$691.72M
Debt
$420.55M
Equity
$1.56B
Working capital
$358.32M
Liquidity
Debt to equity
0.27
Current ratio
3.35
Quick ratio
2.48
Net debt/EBITDA
0.88
Margins
EBITDA margin
26.9%
Gross margin
68%
Net margin
15.1%
Operating margin
25.5%
Efficiency
Return on assets
6.6%
Return on equity
9.3%
Return on invested capital
18.8%
Return on capital employed
7.7%
Return on sales
17.5%
Dividend
Dividend yield
0.25%
DPS
$1.28
Payout ratio
35.4%

TECH stock price

How has the BIO-TECHNE stock price performed over time
Intraday
1.57%
1 week
1.45%
1 month
-5.2%
1 year
87.37%
YTD
59.11%
QTD
4.27%

Financial performance

How have BIO-TECHNE's revenue and profit performed over time
Revenue
$931.03M
Gross profit
$632.85M
Operating income
$237.3M
Net income
$140.41M
Gross margin
68%
Net margin
15.1%
BIO-TECHNE's net margin has shrunk by 51% YoY and by 30% QoQ
The company's operating income has surged by 51% YoY and by 14% QoQ
The net income has decreased by 39% YoY and by 24% from the previous quarter
The gross profit rose by 31% YoY and by 11% QoQ

Growth

What is BIO-TECHNE's growth rate over time

Valuation

What is BIO-TECHNE stock price valuation
P/E
139.57
P/B
12.43
P/S
21.03
EV/EBIT
122.53
EV/EBITDA
79.64
EV/Sales
21.45
TECH's P/E is 134% above its 5-year quarterly average of 59.6 and 79% above its last 4 quarters average of 78.0
TECH's EPS is down by 40% year-on-year and by 24% since the previous quarter
The stock's price to book (P/B) is 97% more than its 5-year quarterly average of 6.3 and 40% more than its last 4 quarters average of 8.9
BIO-TECHNE's equity has increased by 13% YoY
The price to sales (P/S) is 95% higher than the 5-year quarterly average of 10.8 and 31% higher than the last 4 quarters average of 16.0
The revenue has grown by 26% YoY and by 10% from the previous quarter

Efficiency

How efficient is BIO-TECHNE business performance
TECH's return on sales has dropped by 56% year-on-year and by 33% since the previous quarter
BIO-TECHNE's return on equity has decreased by 47% YoY and by 26% QoQ
TECH's return on assets is down by 43% year-on-year and by 27% since the previous quarter
BIO-TECHNE's ROIC has decreased by 38% YoY and by 25% from the previous quarter

Dividends

What is TECH's dividend history
DPS
$1.28
Dividend yield
0.25%
Payout ratio
35.4%
Recent dividends

Financial health

How did BIO-TECHNE financials performed over time
The quick ratio has declined by 33% year-on-year and by 21% since the previous quarter
TECH's current ratio is down by 31% YoY and by 19% from the previous quarter
BIO-TECHNE's debt is 73% lower than its equity
BIO-TECHNE's debt has increased by 44% QoQ but it has decreased by 3% YoY
TECH's debt to equity is up by 42% since the previous quarter but it is down by 13% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.